We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Chemistry Analyzer Completes Ortho Clinical Diagnostics’ Catalogue of VITROS XT Solutions

By LabMedica International staff writers
Posted on 09 Mar 2020
Image: The VITROS XT 3400 Chemistry System (Photo courtesy of Ortho Clinical Diagnostics)
Image: The VITROS XT 3400 Chemistry System (Photo courtesy of Ortho Clinical Diagnostics)
Ortho Clinical Diagnostics (Raritan, NJ, USA) has announced the launch and availability of the VITROS XT 3400 Chemistry System, which completes the company’s catalogue of VITROS XT Solutions.

The new CE-marked VITROS XT 3400 Chemistry System, like the VITROS XT 7600 Integrated System, simultaneously performs two tests frequently ordered together on one VITROS XT MicroSlide, a multi-layered, postage-stamp sized slide which filters out lipids and proteins that can impinge the quality of results, and offers an up-to-40% higher throughput than current slides.

Double assay processing offers a 25% faster turnaround time on a common panel of assays, with an average processing time of 7.5 minutes compared to about 10 minutes for other industry options. Furthermore, the XT MicroSlide allows for the lowest sample volume at 2.7 microliters.

Reduction in external factors that could effect results ensures the accuracy of tests performed on VITROS XT Solutions. Thus, Ortho’s proprietary “dry” chemistry technology does not require water, which eliminates the risk that poor water quality could impact results. In addition, single-use tips and cuvettes eliminate the risk for both sample and reagent carryover.

“Because Every Test is a Life, we make patient care our passion at Ortho Clinical Diagnostics,” said Chris Smith, CEO of Ortho Clinical Diagnostics. “Driven by this, we work diligently to ensure the world’s labs are best equipped to partner with clinicians and medical teams to provide consistently fast, accurate results that help them confidently diagnose, monitor and treat their patients.”

Related Links:
Ortho Clinical Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
HPV Test
Allplex HPV28 Detection
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more